A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Obesity rates for Black children and adolescents are 22.4% in the decade before the pandemic and 35% in the 2 years after the ...

Referral to catheter ablation should not be delayed until the patient loses weight, say researchers for the PRAGUE-25 trial.

Uncover the psychophysiological roots of obesity in India to revolutionize interventions and combat the epidemic effectively.

Sarcopenic obesity, a hidden condition affecting people over 40, causes muscle loss and fat gain without major weight changes ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with ...

Discover how sarcopenic obesity affects 23% of people through hidden muscle loss and fat gain, plus treatment options.

Protagonist is directly going up against Eli Lilly, which is advancing retatrutide, also a triple-G agonist, in a Phase II ...

Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS ...

A new healthy food standard has been announced by the Government with the hope that big businesses will promote healthier ...